FDA clears Advaxis’ IND application to conduct Phase I trial of ADXS-HER2

The US Food and Drug Administration (FDA) has cleared Advaxis’ investigational new drug (IND) application to conduct a Phase I clinical trial of ADXS-HER2 (ADXS31-164) to treat patients with metastatic HER2 expressing solid tumors.

Category One, Showcase, status, Uncategorized, What's Hot